Baishideng Publishing Group

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 88726

Title: Recombinant adeno-associated virus 8-mediated inhibition of microRNA let-7a ameliorates sclerosing cholangitis in a clinically relevant mouse model

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06131948

Position: Peer Reviewer

Academic degree: PhD

Professional title: Doctor, Teacher

Reviewer's Country/Territory: Russia

Author's Country/Territory: China

Manuscript submission date: 2023-10-07

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-10-07 16:38

Reviewer performed review: 2023-10-15 11:12

Review time: 7 Days and 18 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This interesting study investigates the inhibition of let-7a microRNA by rAAV8 in an experimental model of sclerosing cholangitis. Comments: 1. The title of the paper states that sclerosing cholangitis predisposed to cholangiocarcinoma was analyzed. But the paper did not analyze the role of let-7a microRNA inhibition in preventing cholangiocarcinoma. 2. The reference list has only 3 sources from the last 3 years. It is recommended to add references to the latest data. 3. In conclusion, it is recommended to discuss directions for further research and clinical perspectives of the findings.